MARKET

PALI

PALI

Palisade Bio Inc
NASDAQ
1.720
-0.090
-4.97%
After Hours: 1.720 0 0.00% 19:55 12/16 EST
OPEN
1.780
PREV CLOSE
1.810
HIGH
1.830
LOW
1.650
VOLUME
6.76M
TURNOVER
--
52 WEEK HIGH
2.590
52 WEEK LOW
0.5300
MARKET CAP
256.29M
P/E (TTM)
-0.5779
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PALI last week (1208-1212)?
Weekly Report · 1d ago
Weekly Report: what happened at PALI last week (1201-1205)?
Weekly Report · 12/08 09:11
Palisade Bio Approves Key Proposals at Stockholder Meeting
TipRanks · 12/04 21:59
Palisade Bio appoints James Izanec as VP, clinical development
TipRanks · 12/02 13:55
*Palisade Bio Appoints James Izanec Vice Pres, Clinical Development >PALI
Dow Jones · 12/02 13:46
PALISADE BIO STRENGTHENS CLINICAL LEADERSHIP TEAM WITH APPOINTMENT OF JAMES IZANEC, MD, AGAF AS VICE PRESIDENT, CLINICAL DEVELOPMENT
Reuters · 12/02 13:45
Weekly Report: what happened at PALI last week (1124-1128)?
Weekly Report · 12/01 09:10
Tilray Brands, SuperX AI Technology And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Benzinga · 11/28 13:17
More
About PALI
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and advancing therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company’s lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Fibrostenotic Crohn’s disease (FSCD). The Company is conducting a Phase I human clinical trial of its lead product candidate, PALI-2108, for the treatment of UC. In UC mouse models, the Company has demonstrated the dose-dependent efficacy of PALI-2108. It utilizes dextran sodium sulfate (DSS)-induced UC mouse models and targets engagement in oxazolone-induced colitis. PALI-2108 targets the key phosphodiesterase-4 (PDE4) in colon tissues and prevents it from breaking down cyclic Adenosine Monophosphate (cAMP) molecules which regulate inflammation in the body.

Webull offers Palisade Bio Inc stock information, including NASDAQ: PALI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PALI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PALI stock methods without spending real money on the virtual paper trading platform.